ID

27614

Description

Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction; ODM derived from: https://clinicaltrials.gov/show/NCT00938340

Lien

https://clinicaltrials.gov/show/NCT00938340

Mots-clés

Versions (1)
  1. 22/11/2017 22/11/2017 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

22 novembre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Cardiovascular Disease NCT00938340

Anglais

Eligibility Cardiovascular Disease NCT00938340

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age 21 - 60 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
body mass index 25-39 kg/m2
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
ldl cholesterol >110 mg/dl
Description

Low density lipoprotein cholesterol measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0202117
<95 percentile for age and gender for both (based on nhanes data)
Description

Age Percentile | Gender Percentile

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001779
UMLS CUI [1,2]
C1264641
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C1264641
tg < 350 mg/dl
Description

Serum Triglyceride Measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0542495
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
high alcohol consumption > 21 units/week (female subjects) or > 28 units/week (male subjects)
Description

Alcohol consumption High U/week | Gender

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001948
UMLS CUI [1,2]
C0205250
UMLS CUI [1,3]
C0560588
UMLS CUI [2]
C0079399
intake of vitamin and mineral supplements within the past 3 weeks or unwillingness to discontinue for 3 weeks prior to screening and for entire study.
Description

Vitamin supplement | Mineral supplements | Vitamin supplement Discontinue Unwilling | Mineral supplements Discontinue Unwilling

Type de données

boolean

Alias
UMLS CUI [1]
C0681579
UMLS CUI [2]
C0556112
UMLS CUI [3,1]
C0681579
UMLS CUI [3,2]
C1444662
UMLS CUI [3,3]
C0558080
UMLS CUI [4,1]
C0556112
UMLS CUI [4,2]
C1444662
UMLS CUI [4,3]
C0558080
use of prescription cholesterol-lowering or blood pressure-lowering medications during the study
Description

Anticholesteremic Agents Prescription | Antihypertensive Agents Prescription

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003277
UMLS CUI [1,2]
C0033080
UMLS CUI [2,1]
C0003364
UMLS CUI [2,2]
C0033080
intake of other putative cholesterol-lowering supplements (excl. psyllium, fish oil capsules, soy lecithin, phytoestrogens)
Description

Anticholesteremic Agents | Psyllium Exclusive | Fish Oil Oral Capsule Exclusive | Soy Lecithin Exclusive | Phytoestrogens Exclusive

Type de données

boolean

Alias
UMLS CUI [1]
C0003277
UMLS CUI [2,1]
C0033979
UMLS CUI [2,2]
C1548966
UMLS CUI [3,1]
C1617119
UMLS CUI [3,2]
C1548966
UMLS CUI [4,1]
C0872912
UMLS CUI [4,2]
C1548966
UMLS CUI [5,1]
C0071011
UMLS CUI [5,2]
C1548966
intake of anti-inflammatory medications (containing aspirin or nsaids) on a regular basis or if an acute intake, within 48 hours of a test day
Description

Anti-Inflammatory Agents Containing Aspirin | Anti-Inflammatory Agents Containing NSAIDs

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003209
UMLS CUI [1,2]
C0332256
UMLS CUI [1,3]
C0004057
UMLS CUI [2,1]
C0003209
UMLS CUI [2,2]
C0332256
UMLS CUI [2,3]
C0003211
diabetes, liver, kidney, thyroid (unless controlled and stable on replacement medication) or other endocrine disorders from self-reported medical history
Description

Diabetes Mellitus | Liver diseases | Kidney Diseases | Thyroid Diseases | Exception Disease Controlled | Exception Thyroid Disease Stable | Exception Replacement Medication | Endocrine System Diseases

Type de données

boolean

Alias
UMLS CUI [1]
C0011849
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0022658
UMLS CUI [4]
C0040128
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C2911690
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0040128
UMLS CUI [6,3]
C0205360
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0559956
UMLS CUI [7,3]
C0013227
UMLS CUI [8]
C0014130
treatment with drugs acting on the gut, such as ezetimibe, bile acid-binding resins, orlistat
Description

Pharmaceutical Preparations Affecting Gut | ezetimibe | Bile-acid Binding Resin | orlistat

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0699819
UMLS CUI [2]
C1142985
UMLS CUI [3]
C2266924
UMLS CUI [4]
C0076275
dietary restrictions such as a medically prescribed diet, or a slimming diet prior to or during the trial
Description

Restricted diet | Prescribed dietary intake | Slimming diet

Type de données

boolean

Alias
UMLS CUI [1]
C0425422
UMLS CUI [2]
C1261371
UMLS CUI [3]
C0521973
weight loss or gain of 10% body weight or more during a period of 6 months before pre-study examination.
Description

Weight decreased Percent of body weight | Weight Gain Percent of body weight

Type de données

boolean

Alias
UMLS CUI [1,1]
C1262477
UMLS CUI [1,2]
C3476809
UMLS CUI [2,1]
C0043094
UMLS CUI [2,2]
C3476809
blood/plasma donation for reason(s) other than the present study prior to the study (1 month for a male subject or 2 months for a female subject), or during the study
Description

Blood Donation | Exception Clinical Trial Present

Type de données

boolean

Alias
UMLS CUI [1]
C0005794
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0008976
UMLS CUI [2,3]
C0150312
lactation 6 weeks before the start of and during study, pregnant or wishing to become pregnant 3 months before or during the study
Description

Breast Feeding | Pregnancy | Pregnancy, Planned

Type de données

boolean

Alias
UMLS CUI [1]
C0006147
UMLS CUI [2]
C0032961
UMLS CUI [3]
C0032992
Retour au début de la page

Similar models

Eligibility Cardiovascular Disease NCT00938340

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age 21 - 60 years
boolean
C0001779 (UMLS CUI [1])
Body mass index
Item
body mass index 25-39 kg/m2
boolean
C1305855 (UMLS CUI [1])
Low density lipoprotein cholesterol measurement
Item
ldl cholesterol >110 mg/dl
boolean
C0202117 (UMLS CUI [1])
Age Percentile | Gender Percentile
Item
<95 percentile for age and gender for both (based on nhanes data)
boolean
C0001779 (UMLS CUI [1,1])
C1264641 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C1264641 (UMLS CUI [2,2])
Serum Triglyceride Measurement
Item
tg < 350 mg/dl
boolean
C0542495 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Alcohol consumption High U/week | Gender
Item
high alcohol consumption > 21 units/week (female subjects) or > 28 units/week (male subjects)
boolean
C0001948 (UMLS CUI [1,1])
C0205250 (UMLS CUI [1,2])
C0560588 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2])
Vitamin supplement | Mineral supplements | Vitamin supplement Discontinue Unwilling | Mineral supplements Discontinue Unwilling
Item
intake of vitamin and mineral supplements within the past 3 weeks or unwillingness to discontinue for 3 weeks prior to screening and for entire study.
boolean
C0681579 (UMLS CUI [1])
C0556112 (UMLS CUI [2])
C0681579 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
C0558080 (UMLS CUI [3,3])
C0556112 (UMLS CUI [4,1])
C1444662 (UMLS CUI [4,2])
C0558080 (UMLS CUI [4,3])
Anticholesteremic Agents Prescription | Antihypertensive Agents Prescription
Item
use of prescription cholesterol-lowering or blood pressure-lowering medications during the study
boolean
C0003277 (UMLS CUI [1,1])
C0033080 (UMLS CUI [1,2])
C0003364 (UMLS CUI [2,1])
C0033080 (UMLS CUI [2,2])
Anticholesteremic Agents | Psyllium Exclusive | Fish Oil Oral Capsule Exclusive | Soy Lecithin Exclusive | Phytoestrogens Exclusive
Item
intake of other putative cholesterol-lowering supplements (excl. psyllium, fish oil capsules, soy lecithin, phytoestrogens)
boolean
C0003277 (UMLS CUI [1])
C0033979 (UMLS CUI [2,1])
C1548966 (UMLS CUI [2,2])
C1617119 (UMLS CUI [3,1])
C1548966 (UMLS CUI [3,2])
C0872912 (UMLS CUI [4,1])
C1548966 (UMLS CUI [4,2])
C0071011 (UMLS CUI [5,1])
C1548966 (UMLS CUI [5,2])
Anti-Inflammatory Agents Containing Aspirin | Anti-Inflammatory Agents Containing NSAIDs
Item
intake of anti-inflammatory medications (containing aspirin or nsaids) on a regular basis or if an acute intake, within 48 hours of a test day
boolean
C0003209 (UMLS CUI [1,1])
C0332256 (UMLS CUI [1,2])
C0004057 (UMLS CUI [1,3])
C0003209 (UMLS CUI [2,1])
C0332256 (UMLS CUI [2,2])
C0003211 (UMLS CUI [2,3])
Diabetes Mellitus | Liver diseases | Kidney Diseases | Thyroid Diseases | Exception Disease Controlled | Exception Thyroid Disease Stable | Exception Replacement Medication | Endocrine System Diseases
Item
diabetes, liver, kidney, thyroid (unless controlled and stable on replacement medication) or other endocrine disorders from self-reported medical history
boolean
C0011849 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0040128 (UMLS CUI [4])
C1705847 (UMLS CUI [5,1])
C2911690 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0040128 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0559956 (UMLS CUI [7,2])
C0013227 (UMLS CUI [7,3])
C0014130 (UMLS CUI [8])
Pharmaceutical Preparations Affecting Gut | ezetimibe | Bile-acid Binding Resin | orlistat
Item
treatment with drugs acting on the gut, such as ezetimibe, bile acid-binding resins, orlistat
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0699819 (UMLS CUI [1,3])
C1142985 (UMLS CUI [2])
C2266924 (UMLS CUI [3])
C0076275 (UMLS CUI [4])
Restricted diet | Prescribed dietary intake | Slimming diet
Item
dietary restrictions such as a medically prescribed diet, or a slimming diet prior to or during the trial
boolean
C0425422 (UMLS CUI [1])
C1261371 (UMLS CUI [2])
C0521973 (UMLS CUI [3])
Weight decreased Percent of body weight | Weight Gain Percent of body weight
Item
weight loss or gain of 10% body weight or more during a period of 6 months before pre-study examination.
boolean
C1262477 (UMLS CUI [1,1])
C3476809 (UMLS CUI [1,2])
C0043094 (UMLS CUI [2,1])
C3476809 (UMLS CUI [2,2])
Blood Donation | Exception Clinical Trial Present
Item
blood/plasma donation for reason(s) other than the present study prior to the study (1 month for a male subject or 2 months for a female subject), or during the study
boolean
C0005794 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0150312 (UMLS CUI [2,3])
Breast Feeding | Pregnancy | Pregnancy, Planned
Item
lactation 6 weeks before the start of and during study, pregnant or wishing to become pregnant 3 months before or during the study
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial